Healthcare Resource Utilization and Costs of Endometrial Cancer in France From 2016 to 2021 (MOONBEAM Study)

OBJECTIVES: Endometrial cancer (EC) is the fourth most common cancer in women in France, occurring mainly after menopause at a median age at diagnosis of 69 years. This was a retrospective study of patients with EC identified in the French National Health Insurance database ‘Système National des Données de Santé’ (SNDS) from 2016–2021 (MOONBEAM).

METHODS: The MOONBEAM initial metastatic or recurrent (im/r) EC population was built to broadly resemble the primary advanced or first recurrent EC population recruited in a pivotal trial for the anti-programmed cell death protein 1 (PD-1) inhibitor dostarlimab + chemotherapy (NCT03981796, RUBY trial). The Moonbeam study estimated the real-world economic burden associated with im/r EC management, including consultations, exams, treatments (such as surgery, radiotherapy, chemotherapy or hormone therapy) and hospitalizations (for EC management and care for adverse events). These cost items were included in a medico-economic model submitted to the Haute Autorité de santé (HAS), the French Health Technology Assessment body. Real-world evidence (RWE) costs observed in the MOONBEAM study were compared with the estimated costs from the HAS recommendations.

RESULTS: Overall, 23,060 patients with im/r EC were identified in the SNDS. The RWE cost estimates for certain physician consultations, hospitalizations, management of AEs and end-of-life care were higher than those estimated by HAS. In particular, average costs per patient estimated in MOONBEAM and estimated by HAS, respectively, were €39 versus €27 for consultation with a general practitioner, €40 versus €35 for consultation with an oncologist, €4750 versus €1176 per hospitalization for asthenia and €14,660 versus €6065 for end-of-life costs.

CONCLUSIONS: We noted disparities between the costs observed in RWE and those derived from HAS costing recommendations that could partly be explained by the MOONBEAM estimates being more population specific than HAS estimates, demonstrating the importance of using population-specific RWE data, whenever possible.